APOE and early-onset autosomal dominant Alzheimer disease: Similar to baseline, there was no difference in the levels of EPA, DHA or ARA between APOE3 and APOE4 groups after 12 months of n-3 PUFA supplementation (Figures 2A–C), which is consistent with previous n-3 PUFA intervention studies carried out in healthy subjects (47, 48) and after 18 months of DHA supplementation in patients with Alzheimer's disease (49).